Beam Therapeutics (NASDAQ:BEAM) is a gene editing company — one that gets less attention than its peers. Nonetheless, it currently has a $2.7 billion market cap and a diverse portfolio with two disclosed candidates in clinical trials — one targeting sickle cell disease (SCD) and the other T-cell leukemia. However, with initial clinical trial data on the SCD trial not expected until the second half of the year and two peers already gaining regulatory approval in the space, BEAM may find itself too late to the market.
It could be a more speculative investment than its peers, and that’s why I’m neutral on the stock.
How Gene Editing Works
Beam, founded by leading scientists from the CRISPR field, is pursuing therapies for serious diseases using its proprietary base-editing technology. CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats, which reflects the hallmark of a…
Read more…
